Triazolyl piperidine arginine vasopressin receptor modulators

A compound of formula (I),

• or a pharmaceutically acceptable salt thereof, wherein:
• X is —[CH2]a—R or —[CH2]a—O—[CH2]b—R;
• a is 1;
• b is a number selected from 0 to 4;
• R is H, CF3 or Het;
• Het is imidazolyl or triazolyl;
• Y is one to three substituents independently selected from H, halo, CN, C1-6 alkyl, C1-6 alkoxy, wherein said C1-6 alkyl is unbranched and is optionally substituted on its terminal carbon atom with one to three fluoro or one pyrrolidinyl and wherein said C1-6 alkoxy is unbranched and is optionally substituted on its terminal carbon atom with one to three fluoro;
• V is a direct bond;
• Ring A is a piperidine ring, wherein said piperidine ring is optionally substituted with one to three groups selected from C1-6 alkyl, phenyl or hydroxy;
• Q is a direct bond;
• Z is selected from the group consisting of phenyl, pyridyl, quinolinyl, isoquinolinyl, naphthyl, benzoimidazolyl, benzotriazolyl, oxadiazolyl, indazolyl and indolyl, each optionally substituted with one to three groups selected from W;
• W independently at each occurrence is halo, hydroxy, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylSO2, C1-6 alkylSO, C1-6 alkylS, C3-6 cycloalkoxy, C3-6 cycloalkyl, phenyl, phenoxy, pyridinyl, pyrimidinyl, benzyl, benzyloxy or H2NSO2, wherein said C1-6 alkyl or said C1-6 alkoxy are each unbranched and are each optionally substituted on the terminal carbon atom with one to three fluoro.